In a #IOTKI and #SABR era, what is the role of surgery in oligoprogressive #RCC?
We explored:
🔬 Biology of progression
📖 Guideline recommendations
🔪 Surgical outcomes (& CN)
🤝 MDT decision-making
🚧 Research gaps & future directions
@BJUIjournal@grantissimus@BlackmurJames
We’re excited to share our latest research in Elsevier’s Computer Methods and Programs in Biomedicine:
“A numerical simulation study of soft tissue resection for low-damage precision cancer surgery”
https://t.co/SOKzw97peT
The recent DTAS meeting brought together diverse perspectives and forward-thinking ideas. The exchange of insights reaffirmed our shared commitment to advancing surgical innovation through digital twins.
We’re shaping the future of surgery, one digital twin at a time.
Behind every surgery is a story, a person, and a choice.
DTAS is developing digital twins to help surgeons see better, plan smarter, and operate safer.
#PatientFirst#DTAS#SurgicalInnovation
📣 BAUS 2025 is on the horizon (less than a month away!) and we at BSoT are excited about our upcoming sessions
🤔 Will hopefully enthuse urologists at all stages of their careers
📆 Make sure to keep them earmarked in the diary!
@BAUSurology#BAUS25
Top 5 advances in medicine this week (🧵)
1. A vaccine to prevent recurrence of kidney cancer
This is a small trial – 9 patients – all of whom had stage 3 or 4 renal cell carcinoma removed by surgery (removal of the primary tumour, any positive lymph nodes, and any visible metastases)
Tumours were then sequenced, and personalised vaccines made based on the tumour's mutations (its neoantigens)
There was no control group, but in the years that followed it would be expected that cancer would recur in ~50% of patients
In these patients, 0 had recurrence of their cancer
A larger, randomised study is underway
https://t.co/cRLAj3Nn3W
My new textbook "Artificial Intelligence in Urology" is now out in print. Available on Amazon and Elsevier Bookstore. First book of its kind!
A sample of the content and senior authors:
💡Definitions - Andrew J Hung
💡Prostate cancer x Radiomics - Vip Patel
💡Prostate cancer x Genomics - Jim Hu
💡Kidney cancer x Radiomics - Chris Weight
💡Bladder cancer x Pathomics - Joe Liao
💡Testes/Penile/Urethra ca - Hooman Djaladat
💡Kidney stone - Nick Kavoussi
💡Pediatic Urology - Mohan Gundeti
💡Multiomics - Dan Theodorescu
💡Surgical AI - Prokar Dasgupta
💡Autonomous surgery - Axel Krieger
💡Reproductive medicine - Ryan Flanigan
Truly a collaborative effort and amazing coverage of the field of urology.
BAUS Oncology 2024 off to a great start with Advances in Renal Cancer Management.
Comprehensive presentation on Novel Imaging Modalities for Characterising Renal Lesions 🩻 @IztokCaglic - mpMRI to diagnose ccRCC via Clear Cell Likelihood Score (ccLS) in SRM.
#SWIUScholars Weekly Feature📚
"For urology consultants, there was a mean annual increase in the proportion of women that ranged from 4% to 15% across the countries studied."
@albasierrad et al. on rising representation for women urologists across Europe.
https://t.co/DjQPxOG8ii
Thoroughly enjoyed the bladder cancer session #BAUN24 discussing important aspects of intravesical BCG. Thank you to my fellow speakers @chats69@CNSNoble and @BecsWM. Special thanks to @medacPharmaUK.
📰NEWS: @Tom_J_Mitchell has been appointed our new Krishnan-Ang Foundation-funded Group Leader in Urological Cancer.
@grantissimus, co-lead UMVI: “Tom brings world leading expertise in the genomics of kidney cancer"
Read more about Tom's appointment ⬇️
https://t.co/lG93sVDr1l
🎉 Congratulations to the #IP2ATLANTA team for successfully completing recruitment of 4️⃣3️⃣2️⃣ patients! 🤩 An incredible effort from so many sites, teams & individuals over the last five years.
🔗 https://t.co/9NNFxD4hoH
I don’t usually post personal news but Clinicians have told us to pull every lever.
Our daughter has with #dipg Brain cancer. There is no cure and typically 9m life expectancy.
If anyone knows of trials then please get in contact! #braincancer#childrenscancer@CR_UK